Physician profile
Barry King
NPI 1932217502
$1,349.63
in general payments reported to CMS, 2019-2025
14 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $241 · 2023: $321 · 2024: $445 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $425.06 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $171.44 | 2022-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.34 | 2023-2024 | Caplyta |
| Indivior INC. | $123.92 | 2022-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $119.99 | 2022-2025 | Ingrezza |
| Abbvie INC. | $105.54 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $82.93 | 2022-2023 | Spravato |
| Alkermes, INC. | $77.18 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $24.95 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $24.83 | 2024 | Opsumit |
| Idorsia Pharmaceuticals US INC | $17.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.19 | 2023 | Seglentis |
| Merz North America, INC. | $14.18 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.